Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism
Genetic study for KIT mutation was not done. [...]SM without cutaneous involvement was diagnosed. [...]the frequency of clonal mast-cell disease in screened subjects with HVA ranges from 1% to 7.9%.4,5 The risk of anaphylaxis in mastocytosis increases with higher levels of tryptase. [...]more severe...
Gespeichert in:
| Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2019-07, Vol.7 (6), p.2089-2090 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2090 |
|---|---|
| container_issue | 6 |
| container_start_page | 2089 |
| container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
| container_volume | 7 |
| creator | Giavina-Bianchi, Pedro Gonçalves, Danilo Gois Zanandréa, Andressa Borges de Castro, Raísa Garro, Laila Sabino Kalil, Jorge Castells, Mariana |
| description | Genetic study for KIT mutation was not done. [...]SM without cutaneous involvement was diagnosed. [...]the frequency of clonal mast-cell disease in screened subjects with HVA ranges from 1% to 7.9%.4,5 The risk of anaphylaxis in mastocytosis increases with higher levels of tryptase. [...]more severe Hymenoptera HSRs are also associated with higher baseline serum tryptase levels in patients without SM.4,5 Our patient had an abnormal serum tryptase level (17.7 μg/L). [...]the diagnosis is challenging, because drug-specific sIgE tests are unavailable and skin testing presents undetermined sensitivity and specificity.3 Quinolones are one of the substances that may activate mast cells through MRGPRX2, resulting in non–IgE-mediated release of mediators, as described above.7 In conclusion, the excess of mast cells and their MRGPRX2 receptors in patients with mastocytosis may induce anaphylaxis on activation by quinolones. |
| doi_str_mv | 10.1016/j.jaip.2019.01.059 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2251023954</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219819301783</els_id><sourcerecordid>2251023954</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-72bc8a5dd2e91230c49266e0a1b9e070dbb50fbe4d6f3f3feffa3c0ffca459fc3</originalsourceid><addsrcrecordid>eNp9kF9LwzAUxYMobsx9AR-k4HPrTfo34ssYzgkDX_Q5pOkNS1mbrmnFfXsztvlo8pBDOOdc7o-QewoRBZo91VEtTRcxoDwCGkHKr8iUMRqHzP9dXzTlxYTMnavBn4LmkMAtmcSQ8xwKmJLVopXd9rCTP8YFgw32o2ntzrboAtMGjXSDVYfBOuOeg_Whs8MWvQ5sG3gVNKi2sjWuuSM3Wu4czs_vjHytXj-X63Dz8fa-XGxCFad0CHNWqkKmVcWQUxaDSjjLMgRJS46QQ1WWKegSkyrTsb-otYwVaK1kknKt4hl5PPV2vd2P6AZR27Fv_UjBWEqBxTxNvIudXKq3zvWoRdebRvYHQUEc6YlaHOmJIz0BVHh6PvRwrh7LBqu_yIWVN7ycDOgX_DbYC6cMtgor06MaRGXNf_2_lp6BgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2251023954</pqid></control><display><type>article</type><title>Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism</title><source>Alma/SFX Local Collection</source><creator>Giavina-Bianchi, Pedro ; Gonçalves, Danilo Gois ; Zanandréa, Andressa ; Borges de Castro, Raísa ; Garro, Laila Sabino ; Kalil, Jorge ; Castells, Mariana</creator><creatorcontrib>Giavina-Bianchi, Pedro ; Gonçalves, Danilo Gois ; Zanandréa, Andressa ; Borges de Castro, Raísa ; Garro, Laila Sabino ; Kalil, Jorge ; Castells, Mariana</creatorcontrib><description>Genetic study for KIT mutation was not done. [...]SM without cutaneous involvement was diagnosed. [...]the frequency of clonal mast-cell disease in screened subjects with HVA ranges from 1% to 7.9%.4,5 The risk of anaphylaxis in mastocytosis increases with higher levels of tryptase. [...]more severe Hymenoptera HSRs are also associated with higher baseline serum tryptase levels in patients without SM.4,5 Our patient had an abnormal serum tryptase level (17.7 μg/L). [...]the diagnosis is challenging, because drug-specific sIgE tests are unavailable and skin testing presents undetermined sensitivity and specificity.3 Quinolones are one of the substances that may activate mast cells through MRGPRX2, resulting in non–IgE-mediated release of mediators, as described above.7 In conclusion, the excess of mast cells and their MRGPRX2 receptors in patients with mastocytosis may induce anaphylaxis on activation by quinolones.</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2019.01.059</identifier><identifier>PMID: 30797080</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anaphylaxis ; Antibiotics ; Disease ; Immunotherapy ; Mast cells ; Mastocytosis ; Patients ; Quinolones ; Skin tests ; Tryptase</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-07, Vol.7 (6), p.2089-2090</ispartof><rights>2019 American Academy of Allergy, Asthma & Immunology</rights><rights>2019. American Academy of Allergy, Asthma & Immunology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-72bc8a5dd2e91230c49266e0a1b9e070dbb50fbe4d6f3f3feffa3c0ffca459fc3</citedby><cites>FETCH-LOGICAL-c351t-72bc8a5dd2e91230c49266e0a1b9e070dbb50fbe4d6f3f3feffa3c0ffca459fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30797080$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giavina-Bianchi, Pedro</creatorcontrib><creatorcontrib>Gonçalves, Danilo Gois</creatorcontrib><creatorcontrib>Zanandréa, Andressa</creatorcontrib><creatorcontrib>Borges de Castro, Raísa</creatorcontrib><creatorcontrib>Garro, Laila Sabino</creatorcontrib><creatorcontrib>Kalil, Jorge</creatorcontrib><creatorcontrib>Castells, Mariana</creatorcontrib><title>Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>Genetic study for KIT mutation was not done. [...]SM without cutaneous involvement was diagnosed. [...]the frequency of clonal mast-cell disease in screened subjects with HVA ranges from 1% to 7.9%.4,5 The risk of anaphylaxis in mastocytosis increases with higher levels of tryptase. [...]more severe Hymenoptera HSRs are also associated with higher baseline serum tryptase levels in patients without SM.4,5 Our patient had an abnormal serum tryptase level (17.7 μg/L). [...]the diagnosis is challenging, because drug-specific sIgE tests are unavailable and skin testing presents undetermined sensitivity and specificity.3 Quinolones are one of the substances that may activate mast cells through MRGPRX2, resulting in non–IgE-mediated release of mediators, as described above.7 In conclusion, the excess of mast cells and their MRGPRX2 receptors in patients with mastocytosis may induce anaphylaxis on activation by quinolones.</description><subject>Anaphylaxis</subject><subject>Antibiotics</subject><subject>Disease</subject><subject>Immunotherapy</subject><subject>Mast cells</subject><subject>Mastocytosis</subject><subject>Patients</subject><subject>Quinolones</subject><subject>Skin tests</subject><subject>Tryptase</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kF9LwzAUxYMobsx9AR-k4HPrTfo34ssYzgkDX_Q5pOkNS1mbrmnFfXsztvlo8pBDOOdc7o-QewoRBZo91VEtTRcxoDwCGkHKr8iUMRqHzP9dXzTlxYTMnavBn4LmkMAtmcSQ8xwKmJLVopXd9rCTP8YFgw32o2ntzrboAtMGjXSDVYfBOuOeg_Whs8MWvQ5sG3gVNKi2sjWuuSM3Wu4czs_vjHytXj-X63Dz8fa-XGxCFad0CHNWqkKmVcWQUxaDSjjLMgRJS46QQ1WWKegSkyrTsb-otYwVaK1kknKt4hl5PPV2vd2P6AZR27Fv_UjBWEqBxTxNvIudXKq3zvWoRdebRvYHQUEc6YlaHOmJIz0BVHh6PvRwrh7LBqu_yIWVN7ycDOgX_DbYC6cMtgor06MaRGXNf_2_lp6BgQ</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Giavina-Bianchi, Pedro</creator><creator>Gonçalves, Danilo Gois</creator><creator>Zanandréa, Andressa</creator><creator>Borges de Castro, Raísa</creator><creator>Garro, Laila Sabino</creator><creator>Kalil, Jorge</creator><creator>Castells, Mariana</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>201907</creationdate><title>Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism</title><author>Giavina-Bianchi, Pedro ; Gonçalves, Danilo Gois ; Zanandréa, Andressa ; Borges de Castro, Raísa ; Garro, Laila Sabino ; Kalil, Jorge ; Castells, Mariana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-72bc8a5dd2e91230c49266e0a1b9e070dbb50fbe4d6f3f3feffa3c0ffca459fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anaphylaxis</topic><topic>Antibiotics</topic><topic>Disease</topic><topic>Immunotherapy</topic><topic>Mast cells</topic><topic>Mastocytosis</topic><topic>Patients</topic><topic>Quinolones</topic><topic>Skin tests</topic><topic>Tryptase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giavina-Bianchi, Pedro</creatorcontrib><creatorcontrib>Gonçalves, Danilo Gois</creatorcontrib><creatorcontrib>Zanandréa, Andressa</creatorcontrib><creatorcontrib>Borges de Castro, Raísa</creatorcontrib><creatorcontrib>Garro, Laila Sabino</creatorcontrib><creatorcontrib>Kalil, Jorge</creatorcontrib><creatorcontrib>Castells, Mariana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giavina-Bianchi, Pedro</au><au>Gonçalves, Danilo Gois</au><au>Zanandréa, Andressa</au><au>Borges de Castro, Raísa</au><au>Garro, Laila Sabino</au><au>Kalil, Jorge</au><au>Castells, Mariana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2019-07</date><risdate>2019</risdate><volume>7</volume><issue>6</issue><spage>2089</spage><epage>2090</epage><pages>2089-2090</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>Genetic study for KIT mutation was not done. [...]SM without cutaneous involvement was diagnosed. [...]the frequency of clonal mast-cell disease in screened subjects with HVA ranges from 1% to 7.9%.4,5 The risk of anaphylaxis in mastocytosis increases with higher levels of tryptase. [...]more severe Hymenoptera HSRs are also associated with higher baseline serum tryptase levels in patients without SM.4,5 Our patient had an abnormal serum tryptase level (17.7 μg/L). [...]the diagnosis is challenging, because drug-specific sIgE tests are unavailable and skin testing presents undetermined sensitivity and specificity.3 Quinolones are one of the substances that may activate mast cells through MRGPRX2, resulting in non–IgE-mediated release of mediators, as described above.7 In conclusion, the excess of mast cells and their MRGPRX2 receptors in patients with mastocytosis may induce anaphylaxis on activation by quinolones.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30797080</pmid><doi>10.1016/j.jaip.2019.01.059</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-2198 |
| ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-07, Vol.7 (6), p.2089-2090 |
| issn | 2213-2198 2213-2201 |
| language | eng |
| recordid | cdi_proquest_journals_2251023954 |
| source | Alma/SFX Local Collection |
| subjects | Anaphylaxis Antibiotics Disease Immunotherapy Mast cells Mastocytosis Patients Quinolones Skin tests Tryptase |
| title | Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A57%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anaphylaxis%20to%20quinolones%20in%20mastocytosis:%20Hypothesis%20on%20the%20mechanism&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Giavina-Bianchi,%20Pedro&rft.date=2019-07&rft.volume=7&rft.issue=6&rft.spage=2089&rft.epage=2090&rft.pages=2089-2090&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2019.01.059&rft_dat=%3Cproquest_cross%3E2251023954%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2251023954&rft_id=info:pmid/30797080&rft_els_id=S2213219819301783&rfr_iscdi=true |